Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 2/20 | 0.33 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888951 | 0.87 | NPC1 (0.41) | NPC1RAB9ASCN4ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10262492 | 0.83 | LMNA (0.38) | NPC1RAB9ASCN4ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27873008 | 0.81 | SMN1; SMN2 (0.46) | NPC1RAB9ASCN4ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22509970 | 0.81 | NPC1 (0.44) | NPC1RAB9ASCN4ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10263347 | 0.81 | CYP1A2 (0.48) | ALDH1A1KDM4EKMT2AHSD17B10LMNA | |
| SCHEMBL19954926 | 0.80 | OGA (0.46) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL22803642 | 0.79 | MEN1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL15221567 | 0.79 | NR4A2 (0.43) | TP53LMNAHTTTDP1 | |
| SCHEMBL12775197 | 0.79 | MAPT (0.41) | KDM4EMAPTKMT2APTGS1PDE10A | |
| SCHEMBL888873 | 0.78 | AAK1 (0.42) | RAB9AMAPTAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | SHIONOGI & CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | GLP1R, GIPR, GCGR | NPC1 1254/4885RAB9A 639/4885SCN4A 2283/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | NPC1 138/4885RAB9A 572/4885SCN4A 2013/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | NPC1 1541/4885RAB9A 2160/4885SCN4A 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.